Results 1 to 10 of about 45,399 (173)

Magnetic resonance imaging with pathological correlation in a case of mantle cell lymphoma of the parotid gland: a case report [PDF]

open access: yesJournal of Medical Case Reports, 2010
Introduction Mantle cell lymphoma is a rare non-Hodgkin's lymphoma. It is a subtype of B-cell lymphoma with frequent involvement of the bone marrow and the gastrointestinal tract. Isolated parotid gland involvement seldom occurs.
Karakozoglou Thrasivulos   +4 more
doaj   +2 more sources

Mantle cell lymphoma of the larynx: Primary case report [PDF]

open access: yesJournal of Medical Case Reports, 2012
Introduction Primary laryngeal lymphomas are exceedingly rare. Only about a hundred cases have been reported. They consist mainly of non-Hodgkin lymphoma, especially of diffuse large B-cell lymphoma and mucosa-associated lymphoid tissue.
Naciri Sarah   +7 more
doaj   +3 more sources

Primary gastric mantle cell lymphoma [PDF]

open access: yesHematology Reports, 2012
Mantle cell lymphoma represents 2,5-7% all of non Hodgkin’s lymphomas. Stomach is the most common site of extranodal lymphoma. However, that is not the case with mantle cell lymphoma, which is extremely rare.
Duska Petranovic   +7 more
doaj   +5 more sources

Mantle cell lymphoma

open access: yesHaematologica, 2009
This perspective article by Drs. Pileri and Falini examines the diagnosis and bio-pathology of mantle cell lymphoma in the light of the criteria of the WHO Classification and recent reports. See related articles on pages 1555, 1563 and 1595.
Stefano A. Pileri, Brunangelo Falini
doaj   +2 more sources

Smoldering mantle cell lymphoma [PDF]

open access: yesJournal of Experimental & Clinical Cancer Research, 2017
Background Mantle cell lymphoma (MCL) is an aggressive disease, with poor prognosis and a limited survival. However, some patients with indolent MCL can survive beyond 7~10 years. These patients remain largely asymptomatic and can be in observation for a
Haige Ye   +6 more
doaj   +3 more sources

Indolent mantle cell lymphoma

open access: yesHaematologica, 2011
Mantle cell lymphoma (MCL) accounts for approximately 6% of all non-Hodgkin’s lymphomas[1][1] and is characterized by the over-expression of cyclin D1 with cell cycle dysregulation, secondary to the genetic abnormality t(11;14)(q13;q32).[2][2] It often has an aggressive clinical course and ...
Michelle Furtado, Simon Rule
doaj   +3 more sources

Mantle cell lymphoma

open access: yesSeminars in Cancer Biology, 2011
Le lymphome a cellules du manteau (LCM) est une pathologie qui ne represente que 5 a 8 % des lymphomes malins non hodgkiniens. Le LCM se caracterise par la presence de la translocation reciproque entre les chromosomes 11 et 14 (11;14)(q13;q32). Celle-la induit une augmentation de l’expression de la cycline D1, aboutissant au dereglement du cycle ...
Steven Le Gouill   +8 more
  +8 more sources

Case report: Composite mantle cell lymphoma and classical Hodgkin lymphoma

open access: yesPathology and Oncology Research, 2023
Composite mantle cell lymphoma and classical Hodgkin lymphoma is very rare and the actual origin of it is still unclear. Here we reported a new case of composite mantle cell lymphoma and classical Hodgkin lymphoma and analyzed its molecular changes ...
Hongyu Wang   +4 more
doaj   +1 more source

Mantle cell lymphoma

open access: yesBlood Reviews, 1994
The term mantle cell lymphoma (MCL) has been introduced recently, to describe lymphomas related to the primary B follicle and the mantle of the secondary lymphoid follicle. MCL forms a subset of diffuse small cleaved cell lymphomas according to the Working Formulation and correspond closely to the centrocytic lymphomas described in the Kiel ...
C, De Wolf-Peeters, S, Pittaluga
  +6 more sources

Impact of Pre-transplant Induction Therapy on Outcomes of Patients Who Undergo Autologous Stem Cell Transplantation for Mantle Cell Lymphoma in First Complete Remission ☆

open access: yesHematology/Oncology and Stem Cell Therapy, 2023
Mantle cell lymphoma is a rare subtype of non-Hodgkin’s lymphoma with poor prognosis and continue to be challenging to treat. The choice of first line induction regimen remains a topic of debate due paucity of clinical trials.
Omar Albanyan   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy